Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know

Core Viewpoint - Rapt Therapeutics has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system focuses on changes in earnings estimates, which have a strong correlation with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to institutional investors adjusting their valuations, resulting in stock price movements [4]. Company Performance Indicators - For the fiscal year ending December 2025, Rapt Therapeutics is projected to earn -$0.49 per share, reflecting an 84.6% change from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Rapt Therapeutics has increased by 64%, indicating a positive outlook for the company's earnings [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of generating significant returns for top-ranked stocks [7][9]. - Rapt Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].